OR WAIT null SECS
“[Out] of everything going on, this is probably 1 of the most exciting areas in prostate cancer,” says Jason M. Hafron, MD.
In this video, Jason M. Hafron, MD, shares why he thinks PSMA is “disruptive technology” in prostate cancer. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of urology at the William Beaumont School of Medicine, Oakland University; and the director of robotic surgery at Beaumont Hospital Royal Oak in Michigan. He was speaking at the 2021 LUGPA annual meeting.